Leuprolide Side Effects: Safety Signals and Warnings
Leuprolide safety concerns are compound-specific. The main listed side effects are Hot flashes (most common), Decreased libido, and Erectile dysfunction (males). The main warning signals are Tumor flare in first 1-2 weeks - anti-androgen cover recommended for prostate cancer, Bone density monitoring recommended with use >6 months, and Increased cardiovascular and metabolic risk with long-term ADT.
Direct Answer
Leuprolide (Lupron) is FDA-approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty - one of the broadest indication profiles of any peptide drug in this library. With 40+ years of clinical use and extensive Phase 3 data across multiple indications, it is the reference GnRH agonist. A highly validated compound by any standard.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Sexual Health
- Best for
- Prostate cancer hormone therapy, endometriosis, uterine fibroids, precocious puberty, GnRH agonist reference compound
Reported Side Effects
- Hot flashes (most common)
- Decreased libido
- Erectile dysfunction (males)
- Bone mineral density loss
- Injection site reactions
- Mood changes, irritability, depression
- Weight gain
- Fatigue and weakness
Warnings
- Tumor flare in first 1-2 weeks - anti-androgen cover recommended for prostate cancer
- Bone density monitoring recommended with use >6 months
- Increased cardiovascular and metabolic risk with long-term ADT
- Rare reports of pituitary apoplexy in patients with pituitary adenomas
- QT prolongation risk
Known or Plausible Interactions
- Anti-androgens (flare protection - bicalutamide, flutamide, enzalutamide)
- QT-prolonging drugs (additive cardiac risk)
- Bisphosphonates or denosumab (often co-prescribed to prevent bone loss)
- Diabetes medications (glucose monitoring needed - ADT affects insulin sensitivity)
Regulatory Context
FDA-approved prescription medication. Multiple formulations and brand names (Lupron, Eligard, Fensolvi). Not a controlled substance.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Advanced Prostate Cancer (Level A), Endometriosis Management (Level A), Central Precocious Puberty (Level A), and Uterine Fibroid Shrinkage (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Leuprolide Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/leuprolide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.